Subscribe to RSS
DOI: 10.1055/s-0038-1646308
Plasminogen Levels in Healthy Volunteers -Influence of Age, Sex, Smoking and Oral Contraceptives
Publication History
Received 19 March 1992
Accepted after revision 15 June 1992
Publication Date:
04 July 2018 (online)
Summary
There is considerable doubt as to the importance of reduced plasminogen (PLG) activity as a risk factor for venous thrombosis. In the present study we have identified a wide range of PLG activities (25–200%) in a cohort of 9,611 blood donors. Males and females not taking hormonal contraceptives show a similar distribution of PLG, however, variation related to age appears to follow a different pattern in males and females. These differences are of doubtful clinical importance as are differences related to smoking. In contrast, females taking hormonal contraceptives or hormone replacement therapy (HRT) have up to 25% higher mean PLG levels in younger females but a less marked elevation (10%) is seen in 40–50 year olds. A PLG activity <65% was recorded in 61 donors, none of whom appeared to have a history of thrombosis. These findings do not support the notion that reduced PLG is an important thrombophilic risk factor, however, further investigation of the donors with low PLG is required.
-
REFERENCES
- 1 Aoki N, Moroi M, Sakata Y, Yoshida N, Matsuda M. Abnormal Plasminogen. J Clin Invest 1978; 61: 1186-1195
- 2 Kazama M, Tahara C, Suzuki Z, Gohchi K, Abe T. Abnormal Plasminogen, a case of recurrent thrombosis. Thromb Res 1981; 21: 517-522
- 3 Soria J, Soria C, Bertrand O, Dunn F, Drouet L, Caen JP. Plasminogen Paris I: Congenital abnormal plasminogen and its incidence in thrombosis. Thromb Res 1983; 32: 229-238
- 4 Scharrer I, Hach-Wunderle V, Wohl RC, Sinio L, Boreisha I, Robbins KC. Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis. Haemostasis 1988; 18: 77-86
- 5 Robbins KC. Classification of abnormal plasminogens: dysplas-minogenemias. Semin Thromb Hemostas 1990; 16: 217-220
- 6 Kluft C, Verheijen JH, Engesser L. Fibrinolysis and thrombophilia; an introduction. Fibrinolysis 1988; 2 (Suppl2): 1-6
- 7 Girolami A, Lazzaro A, Simioni P. Thrombotic manifestations in plasminogen deficiency and in plasminogen abnormalities. Thromb Haemostas 1988; 60: 528
- 8 Dolan G, Preston FE. Familial plasminogen deficiency and thromboembolism. Fibrinolysis 1988; 2 (Suppl2): 26-34
- 9 Lijnen HR, Collen D. Congenital and acquired deficiences of components of the fibrinolytic system and their relation to bleeding or thrombosis. Fibrinolysis 1989; 3: 67-77
- 10 Shigekiyo T, Uno Y, Tomonari A, Satoh K, Hondo H, Ueda S, Saito S. Type I congenital plasminogen deficiency is not a risk factor for thrombosis. Thromb Haemostas 1992; 67: 189-192
- 11 Hasegawa DK, Tyler BJ, Edson JR. Thrombotic disease in three families with inherited plasminogen deficiency. Blood 1982; 60 (Suppl1) 213a
- 12 Lottenberg R, Dolly FR, Kitchens CS. Recurrent thromboembolic disease and pulmonary hypertension associated with severe hypoplas-minogenemia. Am J Hematol 1985; 19: 181-193
- 13 Mannucci PM, Kluft C, Traas W, Seveso P, D'Angelo A. Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol. Br J Haematol 1986; 63: 753-759
- 14 Leebeek FWG, Knot EAR, ten Cate JW, Traas DW. Severe clinical outcome in a patient with hypoplasminogenemia. Fibrinolysis 1988; 2 (Suppl2): 35-36
- 15 Mayer K, Hartmann H, Immel A, Seitz R, Egbring R. Congenital heterozygote hypoplasminogenemia as a risk factor for thrombosis. Fibrinolysis 1988; 2 (Suppl2): 37-38
- 16 Tabernero MD, Sarmiento RG, Tomas JF, Alberca I. Plasminogen deficiency in a Spanish family. Fibrinolysis 1988; 2 (Suppl2): 40-42
- 17 Dolan G, Greaves M, Cooper P, Preston FE. Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. Br J Haematol 1988; 70: 417-421
- 18 Bertina RM. Prevalence of hereditary thrombophilia and the identification of genetic risk factors. Fibrinolysis 1988; 2 (Suppl2): 07-13
- 19 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic Peptide Substrates. Scully MF, Kakkar VV. (eds) Churchill Livingstone, Edinburgh: 1979. pp 128-140
- 20 Ogston CM, Ogston D. Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease. J Clin Pathol 1966; 19: 352-356
- 21 Dolan G, Cooper P, Jackson P, Brown P, Sampson B, Forman K, Preston FE. Plasma antithrombin III and plasminogen in healthy volunteers. Br J Haematol 1991; 77 (Suppl1) 60
- 22 Akiyama Y, Kazama M, Tahara C, Shimazu C, Otake J, Kamel K, Nakatake T, Sakurai N, Yasumuro Y, Suzuki S, Maeba E, Nishida T. Reference values of hemostasis related factors of healthy Japanese adults I: Circadian fluctuation. Thromb Res 1990; 60: 281-289
- 23 Blomback M, Eneroth P, Landgren B-M, Lagerstrom M, Anderson O. On the intraindividual and gender variability of haemostatic components. Thromb Haemostas 1992; 67: 70-75
- 24 Laurell C-B, Kullander S, Thorell J. Effect of administration of a combined estrogen-progestin contraceptive on the level of individual plasma proteins. Scand J Clin Lab Invest 1967; 21: 337-343
- 25 Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemostas 1982; 48: 283-285
- 26 Peterson RA, Krull PE, Finley P, Ettinger MG. Changes in anti-thrombin III and plasminogen induced by oral contraceptives. Am J Clin Pathol 1970; 53: 468-473
- 27 Alkjaersig N, Fletcher AP, de Ziegler D, Steingold KA, Meldrum DR, Judd HL. Blood coagulation in postmenopausal women given estrogen treatment: Comparison of transdermal and oral administration. J Lab Clin Med 1988; 111: 224-228
- 28 Jespersen J, Petersen KR, Skouby SO. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 1990; 163: 396-403
- 29 Robinson GE, Burren T, Mackie IJ, Bounds W, Walshe K, Faint R, Guillebaud J, Machin SJ. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. BMJ 1991; 302: 269-271
- 30 Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemostas 1988; 60: 361-364
- 31 Lackner H, Javid JP. The clinical significance of plasminogen level. Am J Clin Pathol 1973; 60: 175-181
- 32 Kooistra T, Bosma PJ, Jespersen J, Kluft C. Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. Am J Obstet Gynecol 1990; 163: 404-412
- 33 Miles LA, Ginsberg MH, White JG, Plow EF. Plasminogen interacts with human platelets through two distinct mechanisms. J Clin Invest 1986; 77: 2001-2009
- 34 Stormorken H. The thrombo-haemorrhagic balance. Acta Med Scand (Suppl) 1980; 642: 131-140